Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: insulin and its salts

In 2024, polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: insulin and its salts trade exhibited significant decline, with global flows reaching $443,295,485 and a three-year compound annual growth rate of -41.8% (five-year: -28.4%). The all-time peak of $2,347,737,370 was recorded in 2019; the current level is 81% below that high-water mark.

Over the 30-year observation window (1995–2024), 69% of years recorded positive growth, indicating a predominantly expanding market. Trend momentum is decelerating (-29.0% acceleration).

The supply side is concentrated (Herfindahl-Hirschman Index 0.282). The three largest exporters — Denmark ($254.8M), United States ($73.3M), and India ($51.0M) — collectively dominate supply flows. The leading exporter has grown at -39.9% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.094). The three largest import markets are United States ($85.6M), France ($67.7M), and Mexico ($40.1M). The largest importing market sources from 19 different supplying countries.

The dominant trade corridor is Denmark → United States at $64.4M, representing 75.2% of the importer's total demand.

The volatility score for polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: insulin and its salts is 54 out of 100, classified as medium. Trade flows are moderately variable, typical for goods with seasonal or cyclical demand patterns.

For market entrants, contracting demand signals caution before committing resources. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.